Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600131941) titled 'Anti-pd-1 /CTLA-4 double immune combination antibody reverses the resistance of PD-1 -(L)1 monoclonal antibody by targeting Macro-C1Q in cervical cancer' on Sept. 8.
Study Type: Interventional study
Study Design:
Non randomized control
Primary Sponsor: The 2nd Affiliated Hospital of Chongqing Medical University
Condition:
Metastatic/recurrent cervical cancer
Intervention:
A group:Iparomlimab and Tuvonralimab plus Albumin-Bound Paclitaxel
B group:Iparomlimab and Tuvonralimab
Recruitment Status: Not Recruiting
Phase: 2
Date of First Enrollment: 2026-09-08
Target Sample Size: A group:20;B group:20;C g...